On the other hand, our previous study found that the function of Gankyrin on prognosis was apparent in early stages NSCLC (p-TNM I/II), while not obvious in advanced stage (p-TNM III/IV) patients. Here, PSMD10 is linked to non-small cell lung carcinoma.